Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Carregado – page 41

669 clinical trials in Carregado, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Carregado at a glance
669
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

669 trials in Carregado

Open in trial search

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:AstraZeneca AB

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Hidradenitis

Not recruiting

Study on Amlitelimab for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant
  • Sponsor:Bayer Consumer Care AG

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Gastric cancer

Not recruiting

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Study of Amivantamab with Carboplatin and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Study on Adding Apalutamide to Radiotherapy and LHRH Agonist for High-Risk Patients with Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study on Aficamten for Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Aficamten
  • Sponsor:Cytokinetics Inc.

Study on the Safety and Effectiveness of Inhaled Imatinib (AV-101) for Patients with Pulmonary Arterial Hypertension (PAH)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Carregado

What the registry says about research in the country

01 Nephrology Research

Research focusing on secondary hyperparathyroidism (SHPT) in patients undergoing hemodialysis. Clinical studies aim to evaluate new therapeutic approaches for managing hormone levels in patients with end-stage kidney disease (ESKD).

  • Hormone regulation in dialysis patients
  • SHPT treatment optimization
  • Renal replacement therapy outcomes

Studies evaluate novel treatments' efficacy in reducing parathyroid hormone levels in dialysis patients.

02 Cardiovascular Research

Investigations into atherosclerotic cardiovascular disease among dialysis patients, with particular focus on inflammatory markers. Studies examine the relationship between kidney disease and cardiovascular complications.

  • Cardiovascular outcomes in ESKD
  • Inflammatory biomarkers
  • Dialysis-related cardiovascular complications

Research aims to assess new treatments targeting inflammation in dialysis patients with cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.